Seroconversion and Abundance of IgG Antibodies against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean Population

COVID-19 is a pandemic caused by SARS-CoV-2. In Chile, half a million people have been infected and more than 16,000 have died from COVID-19. As part of the clinical trial NCT04384588, we quantified IgG against S1-RBD of SARS-CoV-2 (anti-RBD) in recovered people in Santiago and evaluated their suita...

Descripción completa

Detalles Bibliográficos
Autores principales: González-Stegmaier, R., Cereceda, K., Briones, J. L., Beltran-Pávez, C., Oyarzún-Arrau, A., Riquelme-Barrios, S., Selman, C., Yarad, F., Mahave, M., Caglevic, C., Morales, R., Aguirre, A., Valiente-Echeverría, F., Soto-Rifo, R., Marsiglia, H., Gazitua, R., Villarroel-Espindola, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901042/
https://www.ncbi.nlm.nih.gov/pubmed/33644235
http://dx.doi.org/10.1155/2021/6680337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901042/
https://www.ncbi.nlm.nih.gov/pubmed/33644235
http://dx.doi.org/10.1155/2021/6680337

Ejemplares similares